Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series
29 Août 2023 - 1:03PM
Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage
biotechnology company developing therapies for patients with kidney
disease (the “Company or “Unicycive”), today announced that Shalabh
Gupta, M.D., Chief Executive Officer was recently featured on the
Nasdaq Amplify Issuer Spotlight interview series. The series
explores how industry leaders within small-cap community are
evolving and navigating challenges in various industries.
A link to the archived interview may be accessed
here and on the Unicycive website under the Investors section:
Events and Presentations.
About Unicycive
Therapeutics
Unicycive Therapeutics is a biotechnology
company developing novel treatments for kidney diseases.
Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a
novel investigational phosphate binding agent being developed for
the treatment of hyperphosphatemia in chronic kidney disease
patients on dialysis. UNI-494 is a patent-protected new chemical
entity in late preclinical development for the treatment of acute
kidney injury. For more information, please visit
www.unicycive.com.
Investor Contact:
ir@unicycive.com(650) 900-5470
SOURCE: Unicycive Therapeutics, Inc.
Unicycive Therapeutics (NASDAQ:UNCY)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Unicycive Therapeutics (NASDAQ:UNCY)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024